Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...

Conventional radiation treatment might slow their growth, but Carter was certain to die. Then his doctors gave him pembrolizumab (Keytruda), a new immunotherapy medication that could spur a patient’s ...

The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes ...

Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

The lenvatinib/pembrolizumab combination is an effective option in patients with progression on or after previous chemotherapy.* *Relevance section written by JCO Senior Deputy Editor Kathy D. Miller, ...